Influenza infection in patients before and after liver transplantation

Liver Transplantation

Volumn 6, Issue 5, 2000, Pages 531-542

  Duchini, Andrea ^a,b   Hendry, R Michael ^a,b   Redfield, David C ^a,b   Pockros, Paul J ^a,b  

^a SCRIPPS CLINIC   (United States)

^b VIRAL AND RICKETTSIAL DISEASE LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; INFLUENZA VACCINE; OSELTAMIVIR; RIMANTADINE; SIALIDASE; UNCLASSIFIED DRUG; ZANAMIVIR;

ADULT; ANTIVIRAL ACTIVITY; ATAXIA; CASE REPORT; CHEMOPROPHYLAXIS; DISEASE CONTROL; DRUG TOLERANCE; GRAFT REJECTION; HUMAN; INFECTION RISK; INFLUENZA; INFLUENZA VIRUS; INSOMNIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; ORTHOMYXOVIRUS; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PSYCHOSIS; RECIPIENT; REVIEW; SYSTEMIC VASCULITIS; TREMOR; VACCINATION;

EID: 0033812391     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2000.9738     Document Type: Article

References (108)

1. Parainfluenza and influenza virus infection in pediatric organ transplant recipients
2. Common emergence of amantadine and rimantadine resistant influenza A viruses in symptomatic immunocompromised adults
3. Hepatic decompensation in patients with cirrhosis during infection with influenza A
4. Orthomyxoviruses
5. Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies
6. Viremia in influenza: Detection by polymerase chain reaction
7. PCR on cerebrospinal fluid to show influenza-associated acute encephalopathy or encephalitis
8. Influenza virus infections and immunity: A review of human and animal models
9. Mouse influenza B virus model of Reye's syndrome. Encephalopathy and microvesicular fatty metamorphosis of the liver by influenza B virus following intravenous administration in mice
10. Influenza B virus model of Reye's syndrome. Evidence for a nonpermissive infection of the liver and brain
11. Experimental influenza B virus toxicity in mice: A possible model for Reye's syndrome
12. Role of influenza B virus in hepatic steatosis and mitochondrial abnormalities in a mouse model of Reye syndrome
13. The sequence of changes in liver and brain in the influenza B virus mouse model of Reye's syndrome
14. Hepatic lipid abnormalities in a chemical/viral mouse model for Reye's syndrome
15. Abnormalities in hepatic fatty-acid metabolism in a surfactant/influenza B virus mouse model for acute encephalopathy
16. Influenza A virus in the mouse: Hepatic and cerebral lesions in a Reye's syndrome-like illness
17. Viremia induced by influenza virus
18. Inhalatory infection of mice with influenza A0/PR8 virus. Detection of the virus in the blood and extrapulmonary organs
19. Salicylate intoxication and influenza in ferrets
20. Potential for hepatic and renal dysfunction during influenza B infection, convalescence, and after induction of secondary viremia
21. Acute alterations in the regulation of lipid metabolism after intravascular re-exposure to a single bolus of homologous virus during influenza B infection in ferrets: Possible model of epiphenomena associated with influenza
22. Pathology of influenza hepatitis in susceptible and genetically resistant mice
23. A non-transmissible cytopathogenic effect of influenza virus in tissue culture accompanied by formation of non-infectious hemagglutinins
24. Virological, immunochemical and cytochemical studies of four HeLa cell lines infected with two strains of influenza virus
25. Abortive replication of influenza virus A/WSN/33 in HeLa229 cells; Defective viral entry and budding processes
26. Inhibition of fatty acid beta oxidation by influenza B virus and salicylic acid in mice: Implications for Reye's syndrome
27. Alterations in antioxidant defenses in lung and liver of mice infected with influenza A virus
28. Increased interleukin-6 levels in nasal lavage samples following experimental influenza A virus infection
29. Nasal cytokine and chemokine responses in experimental influenza A virus infection: Results of a placebo-controlled trial of intravenous zanamivir treatment
30. Evidence for cytokine mediation of disease expression in adults experimentally infected with influenza A virus
31. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense
32. Influenza pneumonia as a complication of autologous bone marrow transplantation
33. Influenza virus pneumonia after renal transplant
34. Influenza following heart transplantation in a patient, an unusual cause of viral pneumonia
35. Influenza A virus infects macrophages and stimulates release of tumor necrosis factor-alpha
36. The disappearance of Reye's syndrome - A public health triumph
37. Reye's syndrome in a young adult
38. Reye's syndrome in the United States from 1981 through 1997
39. Acute liver failure following influenza B infection
40. Changing trends of inborn errors in Reye's syndrome: Rarity is relative
41. The changing clinical pattern of Reye's syndrome, 1982-1990
42. A pandemic warning
43. Influenza A virus infection among hospitalized adult bone marrow transplant recipients
44. Influenza in children with cancer
45. Influenza B infection in pediatric solid organ recipients
46. Influenza A in immunocompromised patients
47. Influenza vaccination in kidney transplant recipients: Cellular and humoral immune responses
48. Epidemic renal transplant rejection associated with influenza A Victoria
49. Virus infections and acute renal transplant rejection
50. Decreased function of a renal transplant after influenza virus infection
51. Association of parainfluenza virus type 3 infection with allograft rejection in a liver transplant recipient
52. Human herpesvirus-6 infection after liver transplantation
53. Persistent cytomegalovirus in liver allografts with chronic rejection
54. CMV-induced class II antigen expression in various rat organs
55. Infection concomitant with pediatric renal allograft rejection
56. Respiratory syncytial virus infection in pediatric renal transplant recipients
57. Epstein-Barr virus mediated graft rejection in heart transplant patients: Implication of the cardiac cytoskeleton
58. Rejection, herpervirus infection and Ki-67 expression in endomyocardial biopsy specimens from heart transplant recipients
59. Enteroviral genome native hearts may influence outcome of patients who undergo cardiac transplantation
60. Respiratory viral infections
61. Influenza B in transplant patients
62. Influenza vaccination following liver transplantation in children
63. Antibody response of pediatric solid organ transplant recipients to immunization against influenza virus
64. The immunogenicity of influenza virus vaccine in solid organ transplant recipients
65. Influenza vaccination in liver transplant recipients
66. Efficacy of influenza vaccination in adult liver transplant recipients
67. Influenza vaccination in heart transplant recipients
68. Antibody response to influenza immunization in patients after heart transplantation
69. Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporine, but not azathioprine
70. Impaired serum antibody response to inactivated influenza A and B vaccine in renal transplant recipients
71. Differential immune response to influenza and pneumococcal vaccination in immunosuppressed patients after heart transplantation
72. Suppression of the humoral response by micophenolate mofetil
73. Serum antibody response to influenza vaccine in pulmonary patients receiving corticosteroids
74. Effective immunization against influenza in pediatric renal transplant recipients
75. Hepatitis B vaccination results in 140 liver transplant recipients
76. Development of novel influenza virus vaccines and vectors
77. The efficacy of attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children
78. Evaluation of bivalent live attenuated influenza A vaccines in children 2 months to 3 years of age: Safety, immunogenicity and dose-response
79. Immunization guidelines for pediatric renal disease
80. Immunizations for the immunocompromised child
81. Systemic vasculitis following influenza vaccination - Report of three cases and review of the literature
82. Microscopic polyangitis after influenza vaccination
83. Safety of influenza vaccine in heart transplant recipients
84. Influenza vaccine does not cause rejection after cardiac transplantation
85. Effect of rimantadine treatment on clinical manifestations and otologic complications in adults experimentally infected with influenza A (H1N1) virus
86. Amantadine and rimantadine prophylaxis of influenza A in nursing homes. A tolerability perspective
87. Pharmacokinetics of rimantadine in patients with chronic liver disease
88. New approaches to influenza chemotherapy. Neuraminidase inhibitors
89. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. GG167 Influenza Study Group
90. Randomized trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infection. The MIST (Management of Influenza in the Southern Hemisphere Trialists) study group
91. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza
92. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: Randomized controlled trials for prevention and treatment
93. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B infections
94. Preclinical development of low toxicity drugs: Focus on zanamivir, an anti-influenza drug
95. Antivirals for pandemic influenza
96. Prolonged shedding of amantadine-resistant influenza A viruses by immunodeficient patients: Detection by polymerase chain reaction-restriction analysis
97. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus
98. Antigenic drift of influenza A (H3N2) in a persistently infected immunocompromised host is similar to that occurring in the community
99. Viral infection and renal transplant rejection
100. Influenza among hospitalized adults with leukemia
101. Influenza A and the virus associated haemophagocytic syndrome: Cluster of three cases in children with acute leukemia
102. Community respiratory viral infection in adult lung transplant recipients
103. Influenza vaccination on renal transplant patients is safe and serologically effective
104. Response to influenza A vaccine among high risk patients
105. Antibody response after influenza immunization in renal transplant patients receiving cyclosporine A or azathioprine
106. Influenza vaccination in renal transplant recipients
107. Antibody response to influenza vaccination in renal transplant patients: Correlation with allograft function
108. Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols